Atossa Therapeutics, Inc. (ATOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atossa Therapeutics, Inc. on August 21, 2025. The report addresses a regulatory matter concerning the continued listing of the Company's common stock on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing compliance status rather than financial performance.
Material Changes
The Company received a notice from Nasdaq on February 21, 2025, stating non-compliance with Listing Rule 5550(a)(2) due to the common stock failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The initial compliance period concluded on August 20, 2025. On August 21, 2025, Nasdaq granted the Company an extension of 180 days to regain compliance, setting a new deadline of February 17, 2026.
Outlook, Risks, and Management Commentary
The notice has no immediate effect on the listing or trading of the Company's common stock. Management intends to actively monitor the bid price and is committed to considering available options to regain compliance. The Company explicitly noted that it may effectuate a reverse stock split if necessary to meet the minimum bid price requirement.
Investor Verification Checklist
- Verify the current trading price of ATOS common stock relative to the $1.00 minimum bid requirement.
- Monitor future announcements regarding the potential implementation of a reverse stock split.
- Confirm the status of the compliance deadline set for February 17, 2026.
- Review the Company's most recent 10-K or 10-Q filings for underlying financial data not included in this 8-K.